Immune check-point in cervical cancer

•The risk of recurrent/metastatic cervical cancer represents a common entity.•The role of immune check-point inhibitors is being tested in cervical cancer.•This is the largest updated analysis of clinical trials in cervical cancer patients.•This analysis suggests that immune check-point inhibitors could influence outcomes in cervical cancer. Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.